HC Wainwright Decreases Earnings Estimates for Precigen

Precigen, Inc. (NASDAQ:PGEN) – HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for Precigen in a note issued to investors on Thursday, May 15th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of ($0.37) per share for the year, down from their prior forecast of ($0.29). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q4 2025 earnings at ($0.04) EPS, FY2026 earnings at ($0.01) EPS, FY2028 earnings at $0.37 EPS and FY2029 earnings at $0.62 EPS.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Precigen in a research note on Thursday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Precigen Price Performance

NASDAQ PGEN opened at $1.45 on Monday. The company has a market cap of $427.99 million, a P/E ratio of -2.64 and a beta of 1.82. The stock has a 50-day moving average of $1.50 and a two-hundred day moving average of $1.30. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The firm had revenue of $1.34 million for the quarter, compared to the consensus estimate of $0.50 million.

Institutional Investors Weigh In On Precigen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. LexAurum Advisors LLC lifted its position in Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after acquiring an additional 417,055 shares during the period. Iridian Asset Management LLC CT lifted its holdings in shares of Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after purchasing an additional 1,465,962 shares during the period. Barclays PLC lifted its holdings in shares of Precigen by 190.4% during the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 124,141 shares during the period. Rhumbline Advisers grew its position in Precigen by 7.3% in the 4th quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 13,338 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Precigen by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock valued at $3,696,000 after buying an additional 53,343 shares during the period. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.